On March 26, Roche Pharmaceuticals and Merck jointly announced that the two sides have formally signed an agreement to cooperate on commercialization of terbertinib in the mainland China market. Terbotinib is the world's first MET inhibitor approved for marketing. It was approved for marketing in China in December 2023. It is used for precise treatment of patients with non-small cell lung cancer by targeting specific targets such as the MeTeX 14 jump mutation.

On March 26, Roche Pharmaceuticals and Merck jointly announced that the two sides have formally signed an agreement to cooperate on commercialization of terbertinib in the mainland China market. Terbotinib is the world's first MET inhibitor approved for marketing. It was approved for marketing in China in December 2023. It is used for precise treatment of patients with non-small cell lung cancer by targeting specific targets such as the MeTeX 14 jump mutation.